You have 9 free searches left this month | to do more
Showing 1 - 25 of
572 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Dasatinib In Waldenström Macroglobulinemia
Recruiting
  • Waldenstrom Macroglobulinemia
  • DASATINIB
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-03-22
Mar 22, 2022
M
Ibrutinib and Ixazomib Citrate in Treating Patients With Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Suspended
  • Recurrent Waldenstrom Macroglobulinemia
  • +2 more
  • Jacksonville, Florida
  • +1 more
2021-08-02
Aug 2, 2021
D
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Active, not recruiting
  • Multiple Myeloma
  • +3 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    2022-03-15
    Mar 15, 2022
    S
    Loncastuximab Tesirine in WM
    Recruiting
    • Waldenstrom Macroglobulinemia
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    2022-03-01
    Mar 1, 2022
    D
    Ibrutinib + Venetoclax in Untreated WM
    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • MYD88 Gene Mutation
    • Boston, Massachusetts
    • +1 more
    2022-04-01
    Apr 1, 2022
    C
    Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
    Recruiting
    • Hyperviscosity Syndrome
    • Waldenstrom Macroglobulinemia
    • fundoscopic picture
    • +2 more
    • Amiens, France
      CHU Amiens
    2021-05-19
    May 19, 2021
    U
    Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
    Active, not recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Waldenstrom Macroglobulinemia (WM)
    • Shingrix vaccine
    • Rochester, New York
      University of Rochester
    2022-02-07
    Feb 7, 2022
    U
    Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
    Not yet recruiting
    • Waldenstrom Macroglobulinemia
    • Venetoclax; Rituximab
    • DRC
    • (no location specified)
    2022-03-09
    Mar 9, 2022
    D
    Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
    Active, not recruiting
    Has Results
    • Waldenstrom Macroglobulinemia
    • Duarte, California
    • +3 more
    2021-04-17
    Apr 17, 2021
    A
    APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
    Recruiting
    • Waldenstrom Macroglobulinemia
    • APG2575 400 mg
    • +2 more
    • Duarte, California
    • +5 more
    2022-02-28
    Feb 28, 2022
    W
    Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
    Recruiting
    • Waldenstrom Macroglobulinemia
    • +6 more
    • New York, New York
      Weill Cornell Medicine
    2021-12-21
    Dec 21, 2021
    C
    Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
    Recruiting
    • Waldenstrom's Disease
    • Waldenstrom Macroglobulinemia
    • bone marrow sample
    • blood sample
    • Amiens, France
      CHU Amiens
    2021-05-17
    May 17, 2021
    C
    Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia - 2020
    Completed
    • Waldenström Macroglobulinemia
    • Blood or bone marrow samples
    • Vandoeuvre les Nancy, France
      CHRU Nancy
    2021-08-01
    Aug 1, 2021
    M
    Covid-19 Vaccine Responsiveness in MM and Waldenstrom
    Not yet recruiting
    • Multiple Myeloma
    • +3 more
      • Boston, Massachusetts
      • +1 more
      2021-03-31
      Mar 31, 2021
      D
      A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
      Active, not recruiting
      Has Results
      • Waldenström Macroglobulinemia
      • Boston, Massachusetts
      • +4 more
      2021-04-21
      Apr 21, 2021
      G
      Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia - 2006
      Terminated
      • Waldenstrom Macroglobulinemia
      • Epratuzumab (hLL2- anti-CD22 humanized antibody)
      • New York, New York
      • +1 more
      2021-08-12
      Aug 12, 2021
      F
      Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
      Active, not recruiting
      • Waldenstrom Macroglobulinemia
      • Tours, France
        Project manager
      2021-06-28
      Jun 28, 2021
      J
      ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy
      Recruiting
      • IgM MGUS
      • +2 more
      • Boston, Massachusetts
      • +1 more
      2022-02-16
      Feb 16, 2022
      E
      Rifaximin in Patients With Monoclonal Gammopathy
      Recruiting
      • IgA Monoclonal Gammopathy
      • +8 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      2021-10-18
      Oct 18, 2021
      J
      A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
      Active, not recruiting
      • Waldenstrom Macroglobulinemia
      • Changchun, China
      • +5 more
      2022-03-24
      Mar 24, 2022
      N
      Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
      Recruiting
      • Waldenstrom Macroglobulinemia
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2022-04-07
        Apr 7, 2022
        S
        Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
        Recruiting
        • Waldenstrom Macroglobulinemia
        • Vancouver, British Columbia, Canada
        • +3 more
        2021-07-23
        Jul 23, 2021
        J
        A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
        Active, not recruiting
        • Waldenstrom Macroglobulinemia
        • Chiba, Japan
        • +8 more
        2022-03-24
        Mar 24, 2022
        K
        R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
        Recruiting
        • Waldenström's Macroglobulinemia
        • Lenalidomide, Bortezomib, Rituximab, Dexamethasone
        • Busan, Sue-gu, Korea, Republic of
          Kosin University Gospel Hospital
        2022-03-31
        Mar 31, 2022
        T
        Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
        Active, not recruiting
        • Waldenstrom Macroglobulinemia
        • Washington, District of Columbia
        • +3 more
        2022-03-22
        Mar 22, 2022